Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapies for unmet medical needs in the US. They offer LUPKYNIS to treat adult lupus nephritis patients. They have a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
Overview
Strengths
- Valued below its Biotechnology peers: P/E 7.6x vs. a median of 20.4x.
- Consistent growth: revenue has compounded at 210.2% a year over 6 years, rising in 5 of them.
- Shareholder-friendly capital allocation: the share count has shrunk by 2.4% a year over the last three years through buybacks.
- ROIC of 20.7% beats 76% of its 128 Biotechnology peers (median 0.0%).
- EBITDA margin of 49.3% beats 88% of its 128 Biotechnology peers (median 0.0%).
- Cheaper than its own history: P/E 7.6x vs. a historical average of 95.2x and P/FCF 16.1x vs. a historical average of 71.9x.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 4 of the last 6 years.
- Our discounted cash flow target price (9.25 USD) is 44% below the current price.
- Unstable profitability: operating margin ranged from -23,978% to 38% over the last 7 years, with operating losses in 5 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 20.2% of total assets.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data